MarginsXMarginsX
Home › Markets › Health Care › PYXS

Pyxis Oncology Inc. (PYXS)

PYXS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.41
-10.76% on the day
Market cap
$168.6M
Micro cap
Revenue · 2025
$13.9M
-14.2% on 2024
Net income · 2025
-$79.6M
-574.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/0001193125-26-118532-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPYXS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001782223
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$13.9M
Net income-$79.6M
Operating income-$84.4M
Net margin-574.5%
Operating margin-609.2%
Revenue growth-14.2%
Cash$15.4M
Total assets$91.5M
P/E (computed)Net income was not positive
P/S (computed)12.2×

Warning signs

Cash runway
0.7 months
$3.9M cash at September 30, 2026
Share count, 1 year
+92.1%
2025-10-31 to 2026-11-04 · +169.9% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$107K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$3.9M cash; operating cash flow -$17.7M a quarter.Report 2026-09-30
Shares outstanding119,607,855 (2026-11-04); 62,264,215 a year earlier; 44,323,046 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-10-01
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $107K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$20.0M-$16.3M$3.9MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$25.3M-$18.2M$18.9MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$23.3M-$26.0M$5.8MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2025
2025-12-31
$11.0M-$18.1M-$10.4M$15.4MNo debt tags$13.9M10-K 2026-03-23
Q3 2025
2025-09-30
$0-$22.0M-$13.3M$8.9MNo debt tagsNeeds four quarters10-Q 2025-11-03
Q2 2025
2025-06-30
$2.8M-$18.4M-$17.3M$10.7MNo debt tagsNeeds four quarters10-Q 2025-08-14
Q1 2025
2025-03-31
Not filed-$21.2M-$22.5M$12.8MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2024
2024-12-31
$0-$35.6M-$19.3M$19.5MNo debt tags$16.1M10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52026-10-01
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-13
Latest proxyDEF 14A2026-10-21

Source: SEC EDGAR submissions feed, 361 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.8%
1 month-14.6%
3 months-47.5%
Year to date+37.4%
1 year-64.7%
From 52-week high-70.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
WHWKWhitehawk Therapeutics Inc.$3.01-1.63%$177.6M
ADCTADC Therapeutics SA Common Shares$1.25-6.72%$159.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier